Weight Loss Drugs

Bank of America is allocating $250 million annually for weight loss drugs for employees. CEO Brian Moynihan reported that GLP-1 medications now make up approximately 13% of the company's total healthcare expenditures.

Eli Lilly reported higher-than-expected earnings as revenue from its weight loss drugs Mounjaro and Zepbound surged, with Mounjaro revenue rising 91% to $9.9 billion and Zepbound generating $4.9 billion.

The article highlights a historical pattern of women being targeted by products with underlying risks, including cosmetics, pharmaceuticals, and modern weight loss drugs. It notes growing public scrutiny, legal actions, and demands for stronger safety standards and transparency from manufacturers.

Novo Nordisk is suing Eli Lilly, alleging that its TV and social media advertisements use outdated trial data to mislead consumers about the efficacy of weight loss drugs Zepbound and Mounjaro compared to rival injections.

Dr. Anil Shah discussed weight loss drugs on ABC7, providing insights into the different medications available.

Weight loss drugs may improve job prospects and dating odds for a specific group. Marriage and cohabitation rates increased by 29% for this group after approximately 18 months.

Medicare is now covering some GLP-1 weight loss drugs at a cost of $50 for many older Americans, making these previously expensive medications more affordable.

The success of weight loss drugs, particularly Zepbound, has generated a $1.3 billion increase in donations to Christian ministries in the U.S. and Canada. This surge in giving is attributed to the growing popularity of these medications.

Medicare has initiated a GLP-1 pilot program. The article highlights that Medicare coverage of these weight loss drugs could benefit millions of people.

Medicare is now covering some GLP-1 weight loss drugs at a cost of $50, making these previously expensive treatments more affordable for many older Americans.

The article discusses the evolving debate around birthright citizenship and mentions Medicare's coverage of weight loss drugs. Demonstrators gathered outside the U.S. Supreme Court on April 1, 2026, to support birthright citizenship.

The Centers for Medicare & Medicaid Services is launching a temporary pilot program to cover weight loss drugs for some seniors, effective through the end of 2027.

U.S. health spending increased by 7.3% in 2025, reaching $5.7 trillion, driven by GLP-1 weight loss drugs and higher healthcare utilization. The spending amounted to $16,500 per person, according to data published in Health Affairs.

The article discusses options available when insurance does not cover GLP-1 medications prescribed for weight loss by a doctor.

The article discusses challenges in obtaining insurance coverage for weight loss drugs and provides guidance on steps to take if insurance denies coverage for obesity medications.

Weight loss drugs like Ozempic and Wegovy are linked to relationship changes, including reduced intimacy and emotional connection. Therapists and doctors report some users experiencing decreased motivation for previously enjoyed activities. Carrie Krawiec, a therapist from Birmingham Maple Clinic, discusses the impact on couples.

Weight loss drugs will become available to Medicare beneficiaries aged 65+ next month through a temporary government program. The Trump administration is bypassing a law prohibiting Medicare from covering obesity drugs by using a demonstration program, extending a transitional 'Bridge' program until 2024 after private insurers refused to participate in the original three-year 'BALANCE' plan.

Some U.S. employers are discontinuing coverage for weight loss drugs as usage increases, with 10% of large employers planning to eliminate the benefit next year due to rising costs.

A monthly GLP-1 drug could reduce the number of injections patients take annually from 52 to 12. This development aims to improve convenience for weight loss drug users.

A study from the University of Pennsylvania School of Medicine found that women using Ozempic-like drugs are 30% less likely to develop breast cancer, suggesting these weight loss medications may also serve as cancer prevention tools.

Researchers from Penn Medicine found that women taking GLP-1 drugs are less likely to be diagnosed with breast cancer, according to a new study. Dr. Celine Gounder analyzed the findings to determine if the drugs caused the difference.

The article discusses a severe new side effect linked to Ozempic, a weight loss drug, with Dr. Sheila warning that these 'super-powered' medications may cause extreme conditions due to a simple mistake. The term 'Darth Vader' is used metaphorically to describe the drug's alarming side effects.

GLP-1 users are turning to telehealth services to access weight loss drugs, providing a convenient and accessible way to manage their weight. This shift towards telehealth highlights the growing demand for remote healthcare solutions. The trend is expected to continue as more people seek online health services.

A CEO is advocating for employer coverage of weight loss drugs like Wegovy for employees, but the high cost of these medications remains a significant barrier. The article highlights the challenge of balancing employee health benefits with affordability.

A healthcare CEO discusses how insurance coverage of weight loss drugs has caused significant financial losses and layoffs, as reported in NBC News' 'The Cost of Denial' series by Anne Thompson.

Scott Disick's fans have expressed concern over his appearance, describing him as 'deathly ill,' while he promotes a platform selling weight loss drugs. The situation has sparked discussions about health risks associated with such products.

Weight loss drugs and bariatric surgery both reduce fat and cause modest muscle loss, altering body composition. While these treatments improve health, they involve trade-offs that impact mortality risk due to muscle's protective role.